BioNTech CEO expects data from late-stage study soon
BioNTech Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly and said the company could file for U.S. approval in mid-November if the data are positive. "We will certainly be smarter in a fortnight," Sahin

Full story is loading. Click here if it doesn't...